Share
John Sundy
John Sundy is the Chief Medical Officer and Head of Research and Development at Seicmic Therapeutic and an Adjunct Professor of Medicine at Duke University. He has a background in immunology and has held senior roles at Gilead Sciences and Pandion Therapeutics. Sundy is also involved with Neutrolis, Inc., the Childhood Arthritis and Rheumatology Research Alliance, and the NIH Immune Tolerance Network. He earned his B.S. from Bucknell University and his M.D./Ph.D. from Hahnemann University.
Frédéric Oudéa, Chairman of the Board, highlighted that the addition of Delbos, Nesmes, and Sundy would enhance the Board’s expertise in finance and science, particularly in immunology. He acknowledged the valuable contributions of outgoing members Souza and Südhof and expressed enthusiasm for the continued diversification of the Board’s profiles and competencies to align with the Group’s strategic goals. The composition of the Board’s specialized committees will be reviewed post the Annual General Meeting.
